http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_35180363896990645ff9eb9718df3db3
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Orkin |
| name | Stuart H Orkin Stuart. H. Orkin Stuart H. Orkin |
| given-name | Stuart H. Stuart. H. Stuart H |
| organization-name | Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, MA;; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;; Harvard Medical School, Boston, MA; and; Howard Hughes Medical Institute, Boston, MA 1 Division of Hematology and Oncology, Children’s Hospital and Dana Farber Cancer Institute, Department of Pediatrics, Harvard Medical School; 2 Howard Hughes Medical Institute, Boston, MA 02115, USA From the Division of Hematology, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO, and the Howard Hughes Medical Institute, Harvard Medical School, Boston, MA. 2Howard Hughes Medical Institute, The Children’s Hospital, Boston, Massachusetts 02115, USA Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA;; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;; Howard Hughes Medical Institute, Harvard Medical School, Boston, MA; and Children's Hospital and the Dana Farber Cancer Institute, Harvard Medical School, Harvard Stem Cell Institute Boston Massachusetts; The Howard Hughes Medical Institute Boston Massachusetts Division of Hematology/Oncology, Boston Children’s Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Howard Hughes Medical Institute, Boston, MA 02115, USA Division of Hematology-Oncology, The Children's Hospital, Boston, Massachusetts 02115; Dana-Farber Cancer Institute, Boston, Massachusetts 02115; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115; Howard Hughes Medical Institute, Boston, Massachusetts 02115 d Division of Hematology and Oncology, Boston Children’s Hospital, Boston, Massachusetts, USA; e Howard Hughes Medical Institute, Boston, Massachusetts, USA; f Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA; g Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Division of Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute; Boston MA USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School; Boston MA USA 1Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.; 7Howard Hughes Medical Institute, Boston, Massachusetts. Division of Hematology/Oncology, Department of Pediatrics, Children’s Hospital and the Dana Farber Cancer Institute, and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115 Division of Hematology/Oncology, Children's Hospital, Dana-Farber Cancer Institute, and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115; Howard Hughes Medical Institute, Boston, Massachusetts 02115 Boston Children's Hospital and Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, USA Dana-Farber/Children's Hospital Cancer Center, Boston, MA 02115;; Harvard Medical School, Boston, MA 02115;; Howard Hughes Medical Institute, Boston, MA 02115; and; Harvard Stem Cell Institute, Cambridge, MA 02138 Dana-Farber Cancer Institute, Children’s Hospital, Boston, MA 02215, USA.; Harvard Medical School, Boston, MA 02215, USA. Department of Pediatric Oncology, Dana–Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA 02215;; Department of Pediatrics,; Howard Hughes Medical Institute, Chevy Chase, MD 20815 Division of Hematology/Oncology, Children's Hospital Boston and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts, USA Departments of Medicine and Pediatrics, Brigham and Women’s Hospital, Dana Farber Cancer Institute, and Children’s Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston MA 02115 3 Division of Hematology-Oncology, Children’s Hospital, Department of Pediatrics, Harvard Medical School, and the Howard Hughes Medical Institute, Boston, MA 02115, USA 1Division of Pediatric Hematology/Oncology, Children's Hospital Boston, Boston, MA 02115; 2Department of Pediatrics; 5Howard Hughes Medical Institute, Boston, MA 02115 Howard Hughes Medical Institute, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children’s Hospital, and Harvard Medical School Cancer Center 1 , 2 , and 3 , 4; Center for Regenerative Medicine 1 , 2 , and 3 , 4; Department of Pathology, Massachusetts General Hospital 1 , 2 , and 3 , 4; Harvard Medical School, Boston, MA 02114 1 , 2 , and 3 , 4; Harvard Stem Cell Institute 5 , 6 , and 7; Department of Stem Cell and Regenerative Biology 5 , 6 , and 7; Howard Hughes Medical Institute, Harvard University, Cambridge, MA 02138 5 , 6 , and 7; Harvard Stem Cell Institute 5 , 6 , and 7; Department of Stem Cell and Regenerative Biology 5 , 6 , and 7; Howard Hughes Medical Institute, Harvard University, Cambridge, MA 02138 5 , 6 , and 7; Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02111 8 Division of Hematology/Oncology, Children’s Hospital Boston and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA.; Howard Hughes Medical Institute, Boston, MA 02115, USA. Division of Hematology-Oncology and Howard Hughes Medical Institute, Children's Hospital, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115 Division of Hematology–Oncology, Children's Hospital and Dana–Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, MA 02115; Howard Hughes Medical Institute, Children's Hospital, Boston, MA 02115; and Ben May Institute for Cancer Research, University of Chicago, Chicago, IL 60637 Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States; Harvard Stem Cell Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, United States Genetics Unit, Children's Service, Massachusetts General Hospital, Boston, Mass. 02114 Division of Hematology-Oncology, Children's Hospital, Boston, Massachusetts 02115; Howard Hughes Medical Institute, Boston, Massachusetts 02115 4Division of Hematology/Oncology, Children's Hospital and Dana Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115 Division of Hematology/Oncology, Children's Hospital, and Dana Farber Cancer Institute, Harvard Medical School, and Howard Hughes Medical Institute, Boston, Massachusetts 02115 Department of Hematology/Oncology, Harvard Medical School, Boston, MA; and Department of Pediatric Oncology, Dana-Farber Cancer Institute/Children's Hospital, Harvard Medical School, Harvard Stem Cell Institute, Howard Hughes Medical Institute, Boston, MA 02115, USA. Dana Farber Cancer Institute and Boston Children's Hospital Harvard Medical School, and Howard Hughes Medical Institute Boston Massachusetts 1Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA;; 2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;; 25Howard Hughes Medical Institute, Chevy Chase, MD; Division of Hematology/Oncology Boston Children's Hospital Boston Massachusetts; Department of Pediatrics Harvard Medical School Boston Massachusetts; Department of Pediatric Oncology Dana‐Farber Cancer Institute Boston Massachusetts; Harvard Stem Cell Institute Harvard University Boston Massachusetts; Howard Hughes Medical Institute Boston Massachusetts From the Department of Hematology-Oncology and Howard Hughes Medical Institute, Children’s Hospital, Boston; the Departments of Adult Oncology and Medicine, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Maine Medical Center Research Institute, South Portland, ME; and the Department of Experimental Hematology, St Jude Children’s Research Hospital, Memphis, TN. Children's Hospital, Boston, MA; Departments of Medicine and Pediatrics, Brigham and Women’s Hospital, Children’s Hospital, and Dana–Farber Cancer Institute, and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115 Division of Hematology/Oncology, Children's Hospital Boston, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; Divisions of Genetics and Endocrinology and Program in Genomics, Children's Hospital Boston, Boston, MA 02115, USA.; Department of Molecular, Cell, and Developmental Biology, University of California at Los Angeles, Los Angeles, CA 90095, USA. Howard Hughes Medical Institute, Beth Israel Deaconess Medical Center, and Department of Neurology, Harvard Medical School, New Research Building Room 0266, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.; Department of Neurology, Program in Neurogenetics, University of California–Los Angeles School of Medicine, Los Angeles, CA 90095, USA.; Victorian Breast Cancer Research Consortium Laboratory, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria 3050, Australia.; Howard Hughes Medical Institute, Division of Hematology-Oncology, Boston Children's Hospital, and Department of Pediatrics, Dana-Farber Cancer Institute, Boston, MA 02115, USA. Harvard Medical School, Boston, MA;; Division of Hematology/Oncology, Boston Children’s Hospital, Boston, MA;; Harvard Stem Cell Institute, Cambridge, MA;; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; and; Howard Hughes Medical Institute, Boston, MA Division of Hematology/Oncology, Children's Hospital Boston, Boston, MA 02115;; Departments of dPediatrics and; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115; and; The Howard Hughes Medical Institute, Boston, MA 02115 Division of Hematology-Oncology, Children's Hospital Boston, Boston, MA;; Dana-Farber Cancer Institute, Boston, MA;; Harvard Medical School, Boston, MA;; Harvard Stem Cell Institute, Boston, MA;; Howard Hughes Medical Institute, Boston, MA Division of Hematology/Oncology, Department of Pediatrics, Harvard Medical School,; Howard Hughes Medical Institute, Children’s Hospital, 300 Longwood Ave, Boston, MA 02115, USA Division of Hematology-Oncology, Children's Hospital and Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115; Howard Hughes Medical Institute, Boston, Massachusetts 02115 1 Division of Hematology/Oncology, Department of Pediatrics, Children’s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; 3 Howard Hughes Medical Institute, Children’s Hospital, Boston MA 02115, USA Boston Children's Hospital Molecular and Cellular Pharmacology Program, Department of Pharmacology, University of Wisconsin Medical School, 1300 University Avenue, 383 Medical Sciences Center, Madison, WI 53706; and Division of Hematology/Oncology, Children's Hospital and the Dana Farber Cancer Institute, Harvard Medical School and Howard Hughes Medical Institute, Boston, MA 02115 Dana Farber Cancer Institute and Children's Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115 From the Department of Hematology/Oncology, Children's Hospital; Department of Pediatric Oncology, Dana Farber Cancer Institute; and Howard Hughes Medical Institute, Boston, MA. Division of Hematology/Oncology, Howard Hughes Medical Institute, Children's Hospital and the Dana Farber Cancer Institute, Harvard Medical School, Boston,MA 02115, USA Division of Hematology-Oncology, Children’s Hospital and the Dana–Farber Cancer Institute, Department of Pediatrics, and the Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115 From the Departments of Medicine and Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital Medical Center, Howard Hughes Medical Institute, and Harvard Medical School, Boston, MA; and the Department of Molecular Oncology and Department of Pharmacokinetics and Metabolism, Genentech Inc, South San Francisco, CA. Dana Farber/Boston Children's Cancer and Blood Disorders Center, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115, USA;; Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115, USA; Division of Hematology and Oncology, Children’s Hospital and Dana Farber Cancer Institute, Department of Pediatric Oncology, and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, USA Division of Hematology-Oncology, Children's Hospital and Dana Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115; Howard Hughes Medical Institute, Boston, Massachusetts 02115 *Division of Hematology-Oncology, Children's Hospital and Dana–Farber Cancer Institute, Harvard Stem Cell Institute, and; Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115 Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA;; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;; Department of Pediatrics, Harvard Medical School and Harvard Stem Cell Institute, Harvard University, Boston, MA; and; Howard Hughes Medical Institute, Boston, MA Howard Hughes Medical Institute, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Children’s Hospital Boston and Harvard Stem Cell Institute, Boston, MA 02115, USA. Division of Hematology-Oncology 2 , Children’s Hospital, and Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115, USA Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana Farber Cancer Institute; Howard Hughes Medical Institute, Harvard Stem Cell Institute 1 ; 2 ; and 3; Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana Farber Cancer Institute 1 ; 2 ; and 3; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115 1 ; 2 ; and 3 Children's Hospital Boston and Dana-Farber Cancer Institute, Harvard Medical School, Howard Hughes Medical Institute, Boston, MA 02115, USA. From the Division of Hematology/Oncology and Howard Hughes Medical Institute, Children's Hospital, Boston; and Dana Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, MA. Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138;; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215;; Division of Hematology/Oncology, Boston Children’s Hospital, Boston, MA 02115;; Department of Pediatrics, Harvard Medical School, Boston, MA 02115;; Howard Hughes Medical Institute, Boston, MA 02115 Division of Hematology-Oncology, Children's Hospital and Dana Farber Cancer Institute, Department of Pediatrics, Harvard Medical School and Howard Hughes Medical Institute, Boston, MA 02115; and Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 6Department of Pediatric Oncology, Children's Hospital, Dana Farber Cancer Institute, Harvard Medical School and Howard Hughes Medical Institute, Boston, MA 02115 Division of Hematology/Oncology, Boston Children’s Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Harvard Stem Cell Institute, Boston, MA; and; Howard Hughes Medical Institute, Boston, MA Division of Hematology-Oncology, Department of Pediatrics, Children's Hospital and Dana-Farber Cancer Institute; Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115 §Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children’s Hospital, Boston, MA 02115;; ¶Harvard Medical School, Boston, MA 02115;; ‖Howard Hughes Medical Institute, Chevy Chase, MD 20815; and Dana Farber Boston Children’s Cancer and Blood Disorders Center and Howard Hughes Medical Institute, Boston, Massachusetts 02215, United States; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115, United States The authors are members of the Panel on Scientific Boundaries for Review, an ad hoc working group of the Center for Scientific Review Advisory Committee, National Institutes of Health. Their affiliations are available at . Comments should be addressed to this Web site and not to individual authors. Dana Farber Cancer Institute, Departments of Pediatric Oncology and Computational Biology; Children's Hospital, Division of Pediatric Hematology-Oncology; Howard Hughes Medical Institute; Harvard Stem Cell Institute, Boston, Massachusetts 02115 From the Division of Hematology/Oncology, Children's Hospital and Dana Farber Cancer Institute; and Department of Pediatrics, Harvard Medical School and the Howard Hughes Medical Institute, Boston, MA. Department of Hematology/Oncology, Children's Hospital and Dana Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts ‡Division of Hematology/Oncology, Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, and Howard Hughes Medical Institute, Boston MA 02115 Department of Pediatric Oncology, Children's Hospital and the Dana Farber Cancer Institute, Harvard Medical School and Howard Hughes Medical Institute, Boston, Massachusetts, USA Department of Pediatric Oncology, Dana–Farber Cancer Institute and Children’s Hospital, Harvard Medical School, Boston, MA 02115; *Department of Pediatric Oncology, Dana–Farber Cancer Institute, and Division of Hematology/Oncology, Children's Hospital Boston, Harvard Medical School,; Harvard Stem Cell Institute, and; Howard Hughes Medical Institute, Boston, MA 02115 Division of Hematology/Oncology, Boston Children’s Hospital and Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02215 3 Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, Massachusetts 02115; Dana-Farber Cancer Institute, Boston, Massachusetts 02115; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115; Howard Hughes Medical Institute, Boston, Massachusetts 02115 Division of Hematology/Oncology, Boston Children's Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115 Division of Hematology-Oncology, Children's Hospital, and Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115; Howard Hughes Medical Institute, Boston, Massachusetts 02115 Department of Pediatric Oncology, Dana–Farber Cancer Institute and Children's Hospital, Harvard Medical School, Boston, MA 02115;; Howard Hughes Medical Institute, Chevy Chase, MD 20815;; Harvard Stem Cell Institute, Boston, MA 02115; and Sir William Dunn School of Pathology, University of Oxford, Oxford 0X1 3RE, England Division of Hematology and Oncology, Childrens Hospital, and the Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115 Division of Hematology/Oncology, Children's Hospital, Department of Pediatrics, Dana-Farber Cancer Institute, and Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts From the Centre de recherche du Centre hospitalier de l'Université de Montréal; the Institut du cancer de Montréal, Montreal, Quebec, Canada; the Division of Hematology/Oncology, Children's Hospital; the Dana Farber Cancer Institute; Howard Hughes Medical Institute, Boston, MA; the Department of Medicine, Université de Montréal, Montreal, Quebec, Canada; and the Department of Physiology, Monash University, Australia. Department of Pediatric Oncology, Dana Farber Cancer Institute and Children's Hospital, Harvard Medical School and the Howard Hughes Medical Institute, Boston, MA 02115 Divisions of Hematology/Oncology and Neurosciences, Children’s Hospital, and Departments of Pediatrics and Neurology, Harvard Medical School, Howard Hughes Medical Institute, Boston, MA 02115 Division of Hematology-Oncology, Children’s Hospital, Boston, Massachusetts 02115; Department of Pediatrics, Boston, Massachusetts 02115; Brigham and Women’s Hospital, Harvard Medical School and Howard Hughes Medical Institute, Boston, Massachusetts 02115 Departments of Medicine, Pediatrics, and Genetics at Harvard Medical School, Boston, Massachusetts; Hematology Division, Children's Hospital and Dana-Farber Cancer Institute, Boston. Stem Cell Program and Division of Hematology/Oncology, Howard Hughes Medical Institute, Boston's Children's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, United States; Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, United States Howard Hughes Medical Institute and Division of Neuroscience; Children's Hospital, and Department of Neurobiology, Harvard Medical School and Dana Farber Cancer Institute, Boston, Massachusetts 02115 1Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.; 2Harvard Medical School, Boston, Massachusetts.; 3Harvard Stem Cell Institute, Cambridge, Massachusetts.; 4Howard Hughes Medical Institute, Boston, Massachusetts. Division of Hematology/Oncology, Children's Hospital Boston, Boston, MA 02115;; Department of Pediatric Oncology, Dana–Farber Cancer Institute, Boston, MA 02115; Department of Pediatrics, Children's Hospital and the Dana Farber Cancer Institute, Harvard Medical School and the Howard Hughes Medical Institute, Boston, Massachusetts 02115; Howard Hughes Medical Institute.; Division of Hematology/Oncology, Children’s Hospital Boston and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA. Division of Hematology/Oncology, Boston Children’s Hospital, Boston, MA 02115;; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115;; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138;; Department of Pediatrics, Harvard Medical School, Boston, MA 02115;; Howard Hughes Medical Institute, Boston, MA 02115 Children's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Harvard Stem Cell Institute, Cambridge, Massachusetts, USA; Howard Hughes Medical Institute, Boston, Massachusetts, USA Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA;; Howard Hughes Medical Institute, Boston, MA; and From the Department of Pediatrics, Division of Hematology/Oncology, Children's Hospital, the Dana Farber Cancer Institute, and the Howard Hughes Medical Institute, Harvard Medical School, Boston, MA. Division of Hematology/Oncology, Children's Hospital and Dana–Farber Cancer Institute, Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA 02115; and Department of Medicine, Cardiology Division and Department of Cell and Developmental Biology, University of Pennsylvania Health System, Philadelphia, PA 19104 Hematology Division, Children's Hospital, and Departments of Medicine and Pediatrics, Harvard Medical School, Boston, MA 02115. Department of Pediatric Oncology, Children's Hospital, Dana Farber Cancer Institute, Harvard Medical School and Howard Hughes Medical Institute, Boston, MA; Division of Hematology/Oncology, Boston Children’s Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.; Howard Hughes Medical Institute, Boston, MA 02115, USA. Division of Hematology-Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. From the Division of Hematology-Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Harvard Medical School; and Howard Hughes Medical Institute (HHMI), Boston, MA. From the Division of Hematology/Oncology, Department of Medicine, Children's Hospital and Harvard Medical School, Boston; Howard Hughes Medical Institute, Boston; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; and Division of Medical Genetics, Department of Medicine, University of Washington, Seattle. Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Stem Cell Institute and Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115 Division of Hematology/Oncology, The Children's Hospital Medical Center, and Dana Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Howard Hughes Medical Institute, Boston, MA 02115; and Howard Hughes Medical Institute, Division of Nucleic Acids Enzymology, Department of Biochemistry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, NJ 08854 Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115;; Howard Hughes Medical Institute, Boston, MA 02115 Division of Hematology and Oncology, Children's Hospital and Dana Farber Cancer Center, and Howard Hughes Medical Institute, Boston, Massachusetts 02115 From the Hematology/Oncology Division, Harvard Institute of Medicine, Harvard Medical School, and the Hematology/Oncology Division, Children's Hospital and the Dana Farber Cancer Institute, the Department of Pediatrics, Harvard Medical School, Howard Hughes Medical Institute, Boston, MA; and the Department of Immunology and Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA. Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104; Departments of Cell Biology and Pediatrics, Children’s Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115; and Institute for Molecular Biology, University of Zurich, Zurich, Switzerland Division of Hematology-Oncology, Children’s Hospital and Dana Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Howard Hughes Medical Institute, Boston, MA, USA Australia, and Division of Hematology/Oncology, Children's Hospital, Dana-Farber Cancer Institute and Department of Pediatrics, Harvard Medical School, and Howard Hughes Medical Institute, Boston, Massachusetts 02115 From Ontogeny, Inc, Cambridge, MA; the Division of Hematology-Oncology, Children’s Hospital, Dana-Farber Cancer Institute and the Department of Pediatrics, Harvard Medical School, Boston, MA; the Department of Medicine, Committee on Immunology, University of Chicago, Chicago, IL; the Division of Hematology, Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA; and the Howard Hughes Medical Institute, Boston, MA. Division of Hematology/Oncology, Children's Hospital, Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, and Howard Hughes Medical Institute, Boston, Massachusetts 02115 From the Division of Hematology/Oncology, Children's Hospital Boston and the Dana-Farber Cancer Institute, Harvard Medical School, Howard Hughes Medical Institute, Boston, MA. Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02215;; Department of Hematology/Oncology, Boston Children’s Hospital, Boston, MA 02115;; Harvard Medical School, Boston, MA 02115;; Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115;; Howard Hughes Medical institute, Boston, MA 02115 Division of Hematology/Oncology Boston Children's Hospital and Harvard Medical School Boston Massachuetts; Department of Pediatric Oncology Dana‐Farber Cancer Institute Boston Massachuetts; Howard Hughes Medical Institute Cambridge Massachuetts; Harvard Stem Cell Institute, Harvard University Cambridge Massachuetts Dana Farber Cancer Institute and Boston Children's Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA. Division of Hematology/Oncology, Boston Children’s Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115; and; Howard Hughes Medical Institute, Boston, MA 02115 Division of Hematology/Oncology, Children’s Hospital, Dana-Farber Cancer Institute, and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115; Howard Hughes Medical Institute, Boston, Massachusetts 02115 Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9AE, United Kingdom; Department of Hematology-Oncology, Harvard Medical School, Boston, MA 02115; Howard Hughes Medical Institute, Children's Hospital, Boston, MA 02115; Division of Hematology-Oncology, Departments of Internal Medicine and Biological Chemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, MO 63110; and Department of Biochemistry and Biophysics, Iowa State University, Ames, IA... From the Max-Planck-Institute for Physiological and Clinical Research, Bad Nauheim, Germany; the Center for Molecular Medicine, University of Köln, Köln, Germany; and the Howard Hughes Medical Institute, Harvard Medical School, Boston, MA. 1Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.; 2Howard Hughes Medical Institute, Boston, Massachusetts. Department of Biochemistry and Molecular Biology, Graduate Program in Genes and Development, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030; and Division of Hematology/Oncology, The Children's Hospital and Dana–Farber Cancer Institute and Howard Hughes Medical Institute, Boston, MA 02115 Division of Hematology-Oncology, Children’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115; Department of Pediatrics, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115 Harvard Medical School, Boston, MA;; Division of Hematology/Oncology, Boston Children’s Hospital, Boston, MA;; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; and; Howard Hughes Medical Institute, Boston, MA Department of Pediatrics, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115 Division of Hematology-Oncology, Children’s Hospital, Dana-Farber Cancer Institute, and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115; Howard Hughes Medical Institute, Boston, Massachusetts 02115 Division of Hematology/Oncology, Boston Children’s Hospital, Boston, United States; Harvard Stem Cell Institute, Harvard University, Cambridge, United States; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, United States; Howard Hughes Medical Institute, Boston, United States Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;; Division of Hematology/Oncology, Children's Hospital Boston, Harvard Medical School, MA;; Howard Hughes Medical Institute, Boston, MA;; Harvard Stem Cell Institute, Boston, MA; Division of Hematology/Oncology, Boston Children’s Hospital, Boston, United States; Howard Hughes Medical Institute, Boston, United States; Department of Pediatric Oncology, Dana-Farber Cancer Institute (DFCI), Boston, United States; Harvard Stem Cell Institute, Harvard Medical School, Boston, United States *Division of Hematology-Oncology, Children's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Harvard Stem Cell Institute, and; Howard Hughes Medical Institute, Boston, MA 02115 3Division of Hematology/Oncology, The Children's Hospital Medical Center, and Dana Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Howard Hughes Medical Institute, Boston, MA 02115 From the Division of Cardiovascular Medicine (V.N.P., R.C.J., K.W., A.H., K.A.C., Y.Z., B.A.M., J.L., S.Y.C.) and Division of Pulmonary and Critical Care (R.S.S., A.B.W., K.J.H.), Department of Medicine, Brigham and Women's Hospital, Boston, MA; Center for Complex Network Research, Northeastern University, Boston, MA (S.R., N.G., A.B.); Taconic Artemis GmbH, Cologne, Germany (J.C.H.); Division of Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute, Boston, MA (Y.F., S.H... Division of Hematology-Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, United States; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States Division of Hematology/Oncology,Howard Hughes Medical Institute, Children’s Hospital and the Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115 Division of Hematology/Oncology, Children's Hospital and Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School; Howard Hughes Medical Institute, Children's Hospital, Boston, Massachusetts 02115 Children's Hospital of Boston, 300 Longwood Avenue, Boston, MA 02115;; Department of Pediatric Oncology, Dana–Farber Cancer Institute, Boston, MA 02115; Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA; Boston Children's Hospital Boston MA USA; Harvard Medical School Boston MA USA; Dana‐Farber Cancer Institute Boston MA USA; Harvard Stem Cell Institute Cambridge MA USA; Howard Hughes Medical Institute Boston MA USA Division of Genetics, Brigham and Women's Hospital; Division of Emergency Medicine, Department of Medicine, and Division of Hematology and Oncology, Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; and Dana-Farber Cancer Institute, Boston, Massachusetts Harvard Medical School, and Howard Hughes Medical Institute, Boston, Massachusetts 02115 From the Department of Cardiology (A.H., Q.M., J.C., A.v.G., P.Z., B.Z., M.H., S.W.K., W.T.P.), Children's Hospital Boston and Harvard Medical School, Boston, MA; Department of Pediatric Oncology (H.X., S.H.O.), Dana-Farber Cancer Institute, Children's Hospital Boston, and Harvard Medical School, Boston, MA; Children's Hospital Informatics Program at Harvard-MIT (S.W.K.), Division of Health Sciences and Technology, Department of Medicine, Children's Hospital Boston, Boston, MA; Department of... Division of Hematology-Oncology, Children's Hospital, The Sidney Farber Cancer Institute, Department of Pediatrics and Committee on Cell and Developmental Biology, Harvard Medical School, Boston, Massachusetts 02115, USA Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115;; Harvard Stem Cell Institute,; Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115; and Division of Hematology/Oncology, Children’s Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts 02115; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115; Howard Hughes Medical Institute, Boston, Massachusetts 02115 Department of Pediatrics, Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Leukocyte Biology Section, Division of Biomedical Sciences, Faculty of Medicine, Imperial College, London SW7 2AZ, UK.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02111, USA.; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.; Department of Pediatric Oncology, Dana Farber Cancer Institute and Children's Hospital, Harvard Medical School and the Howard Hughes Medical Institute, Boston, MA 02115, USA. Division of Hematology and Oncology, Children's Hospital and Dana Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School Boston Massachusetts 02115 USA Department of Pediatric Oncology Dana‐Farber Cancer Institute and Division of Hematology/Oncology Children's Hospital Boston Howard Hughes Medical Institute Harvard Stem Cell Institute Harvard Medical School Boston MA USA Department of Biochemistry and Molecular Biology, Graduate Program in Genes and Development, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030; and Department of Pediatric Oncology, Children's Hospital and Dana Farber Cancer Institute, Harvard Medical School and Howard Hughes Medical Institute, Boston, MA 02115 M.A.K. and S.H.O. are at the Division of Hematology/Oncology, Children’s Hospital Boston and the Dana Farber Cancer Institute, Harvard Medical School and Howard Hughes Medical Institute, Boston, MA 02115 Dana Farber Cancer Institute, Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, Massachusetts Division of Hematology/Oncology, Boston Children’s Hospital, Boston, MA 02115, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Harvard Medical School, Boston, MA 02115, USA.; Howard Hughes Medical Institute, Boston, MA 02115, USA. |
Incoming Links
Total number of triples: 614.